Moore Capital Management LP Sells 162,329 Shares of Baxter International Inc. $BAX

Moore Capital Management LP lessened its position in shares of Baxter International Inc. (NYSE:BAX) by 45.8% in the second quarter, Holdings Channel reports. The fund owned 192,227 shares of the medical instruments supplier’s stock after selling 162,329 shares during the quarter. Moore Capital Management LP’s holdings in Baxter International were worth $4,098,000 as of its most recent filing with the SEC.

A number of other institutional investors also recently bought and sold shares of BAX. New Mexico Educational Retirement Board boosted its position in Baxter International by 5.8% in the second quarter. New Mexico Educational Retirement Board now owns 25,661 shares of the medical instruments supplier’s stock worth $547,000 after purchasing an additional 1,400 shares during the last quarter. Mufg Securities Americas Inc. increased its position in shares of Baxter International by 9.3% during the 2nd quarter. Mufg Securities Americas Inc. now owns 15,556 shares of the medical instruments supplier’s stock valued at $332,000 after purchasing an additional 1,320 shares during the last quarter. Hsbc Holdings PLC increased its position in shares of Baxter International by 11.0% during the 2nd quarter. Hsbc Holdings PLC now owns 691,167 shares of the medical instruments supplier’s stock valued at $14,748,000 after purchasing an additional 68,302 shares during the last quarter. Wellington Management Group LLP lifted its stake in shares of Baxter International by 276.2% in the 2nd quarter. Wellington Management Group LLP now owns 137,400 shares of the medical instruments supplier’s stock worth $2,929,000 after purchasing an additional 100,875 shares during the period. Finally, Empowered Funds LLC bought a new position in shares of Baxter International in the 2nd quarter worth approximately $1,240,000. Institutional investors own 90.19% of the company’s stock.

Analyst Upgrades and Downgrades

Several analysts recently issued reports on the stock. Wells Fargo & Company boosted their target price on shares of Baxter International from $19.00 to $23.00 and gave the company an “equal weight” rating in a research report on Friday, July 31st. TD Cowen increased their price target on shares of Baxter International from $20.00 to $24.00 and gave the stock a “hold” rating in a research report on Monday, July 27th. UBS Group lifted their price target on shares of Baxter International from $19.00 to $25.00 and gave the stock a “hold” rating in a research note on Tuesday, July 28th. The Goldman Sachs Group boosted their price objective on shares of Baxter International from $19.00 to $21.00 and gave the company a “neutral” rating in a research report on Wednesday, July 15th. Finally, Weiss Ratings upgraded Baxter International from a “sell (d-)” rating to a “sell (d)” rating in a research note on Friday, July 31st. Two analysts have rated the stock with a Buy rating, nine have issued a Hold rating and two have issued a Sell rating to the company. According to MarketBeat.com, Baxter International presently has a consensus rating of “Hold” and a consensus price target of $22.45.

Baxter International Trading Down 0.2%

Shares of NYSE:BAX opened at $26.08 on Tuesday. The stock has a 50 day moving average of $24.37 and a 200 day moving average of $20.57. The company has a market cap of $13.48 billion, a PE ratio of -12.60, a price-to-earnings-growth ratio of 3.96 and a beta of 0.59. Baxter International Inc. has a 12-month low of $15.73 and a 12-month high of $30.00. The company has a current ratio of 1.95, a quick ratio of 1.32 and a debt-to-equity ratio of 1.39.

Baxter International (NYSE:BAX) last released its earnings results on Thursday, July 30th. The medical instruments supplier reported $0.56 EPS for the quarter, topping analysts’ consensus estimates of $0.37 by $0.19. The company had revenue of $2.96 billion for the quarter, compared to analysts’ expectations of $2.80 billion. Baxter International had a negative net margin of 9.27% and a positive return on equity of 16.57%. The firm’s revenue was up 5.3% compared to the same quarter last year. During the same quarter last year, the business earned $0.59 EPS. Baxter International has set its FY 2026 guidance at 1.950-2.150 EPS. As a group, equities research analysts expect that Baxter International Inc. will post 2.04 EPS for the current year.

Baxter International Announces Dividend

The company also recently announced a quarterly dividend, which will be paid on Thursday, October 1st. Investors of record on Friday, August 28th will be issued a $0.01 dividend. The ex-dividend date of this dividend is Friday, August 28th. This represents a $0.04 annualized dividend and a yield of 0.2%. Baxter International’s dividend payout ratio is currently -1.93%.

Baxter International Profile

Baxter International Inc is a global healthcare company that develops, manufactures and markets a broad portfolio of medical products, pharmaceutical therapies and biotechnology-based solutions. The company’s primary business activities are organized around renal care, medication delivery, acute therapies, pharmacy automation, surgical care and biotechnology. Baxter’s offerings are designed to support patient care in hospitals, dialysis centers, nursing homes and other healthcare facilities worldwide.

In the renal care segment, Baxter provides hemodialysis and peritoneal dialysis systems, water treatment equipment and related disposables, including dialyzers, bloodlines and catheters.